[Code of Federal Regulations]
[Title 40, Volume 31]
[Revised as of July 1, 2006]
From the U.S. Government Printing Office via GPO Access
[CITE: 40CFR799.9325]
[Page 354-360]
TITLE 40--PROTECTION OF ENVIRONMENT
CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)
PART 799_IDENTIFICATION OF SPECIFIC CHEMICAL SUBSTANCE AND MIXTURE
TESTING REQUIREMENTS--Table of Contents
Subpart H_Health Effects Test Guidelines
Sec. 799.9325 TSCA 90-day dermal toxicity.
(a) Scope. This section is intended to meet the testing requirements
under section 4 of the Toxic Substances Control Act (TSCA). In the
assessment and evaluation of the toxic characteristics of a chemical,
the determination of subchronic dermal toxicity may be carried out after
initial information on toxicity has been obtained by acute testing. The
subchronic dermal study has been designed to permit the determination of
the no-observed-effects level (NOEL) and toxic effects associated with
continuous or repeated exposure to a test substance for a period of 90
days. This study is not capable of determining those effects that have a
long latency period for development (e.g., carcinogenicity and life
shortening). Extrapolation from the results of this study to humans is
valid only to a limited degree. It can, however, provide useful
information on the degree of percutaneous absorption, target organs, the
possibilities of accumulation, and can be of use in selecting dose
levels for chronic studies and for establishing safety criteria for
human exposure.
(b) Source. The source material used in developing this TSCA test
guideline is the Office of Prevention, Pesticides, and Toxic Substances
(OPPTS) harmonized test guideline 870.3250 (August 1998, final
guideline). This source is available at the address in paragraph (h) of
this section.
(c) Definitions. The following definitions also apply to this
section.
Cumulative toxicity is the adverse effect of repeated doses
occurring as a result of prolonged action or increased concentration of
the administered test substance or its metabolites in susceptible
tissues.
Dose in a subchronic dermal study is the amount of test substance
applied daily to the skin for 90 days. Dose is expressed as weight of
the test substance (grams, milligrams), per unit body weight of test
animal (milligrams per kilogram), or as weight of the test substance per
unit of surface area (milligrams per square centimeter) per day.
No-observed-effects level (NOEL) is the maximum dose used in a study
which produces no adverse effects. The NOEL is expressed in terms of the
weight of a test substance given daily per unit weight of test animal
(milligrams per kilogram per day).
[[Page 355]]
Subchronic dermal toxicity is the adverse effects occurring as a
result of the repeated daily exposure of experimental animals to a
chemical by the dermal route for a part of the test animal's life span.
Target organ is any organ of a test animal showing evidence of an
effect induced by a test substance.
(d) Limit test. If a test at one dose level of at least 1,000 mg/kg
body weight (expected human exposure may indicate the need for a higher
dose level), using the procedures described for this section, produces
no observable toxic effects or if toxic effects would not be expected
based upon data on structurally related compounds, a full study using
three dose levels might not be necessary.
(e) Test procedures--(1) Animal selection--(i) Species and strain. A
mammalian species must be used for testing. The rat, rabbit, or guinea
pig may be used. Commonly used laboratory strains must be employed. If
other mammalian species are used, the tester must provide justification/
reasoning for their selection. When a subchronic dermal study is
conducted as a preliminary to a chronic dermal study, the same species
and strain must be used in both studies.
(ii) Age/weight. (A) Testing should be started with young healthy
animals as soon as possible after weaning and acclimatization.
(B) Dosing should generally begin in guinea pigs between 5-6 weeks
of age, in rats between 8-9 weeks of age, and in rabbits at least 12
weeks old.
(C) At the commencement of the study, the weight variation of
animals used must be within 20% of the mean weight for each sex.
(iii) Sex. Equal numbers of animals of each sex with healthy skin
must be used at each dose level. The females shall be nulliparous and
nonpregnant except for specially designed studies.
(iv) Numbers. (A) At least 20 animals (10 animals per sex) must be
used at each dose level.
(B) If interim sacrifices are planned, the number must be increased
by the number of animals scheduled to be sacrificed before completion of
the study.
(C) To avoid bias, the use of adequate randomization procedures for
the proper allocation of animals to test and control groups is required.
(D) Each animal must be assigned a unique identification number.
Dead animals, their preserved organs and tissues, and microscopic slides
must be identified by reference to the animal's unique number.
(v) Husbandry. (A) Animals should be housed in individual cages.
(B) The temperature of the experimental animal rooms should be at 22
3 [deg]C
(C) The relative humidity of the experimental animal rooms should be
50 20%.
(D) Where lighting is artificial, the sequence should be 12 hours
light/12 hours dark.
(E) Control and test animals must be fed from the same batch and
lot. The feed should be analyzed to assure adequacy of nutritional
requirements of the species tested and for impurities that might
influence the outcome of the test. For feeding, conventional laboratory
diets may be used with an unlimited supply of drinking water.
(F) The study should not be initiated until animals have been
allowed a period of acclimatization/quarantine to environmental
conditions, nor should animals from outside sources be placed on test
without an adequate period of quarantine. An acclimation period of at
least five days is recommended.
(2) Control and test substances. (i) Where necessary, the test
substance is dissolved or suspended in a suitable vehicle. If a vehicle
or diluent is needed, the vehicle should not elicit toxic effects or
substantially alter the chemical or toxicological properties of the test
substance. It is recommended that, whenever possible, the usage of an
aqueous solution be considered first, followed by consideration of a
solution of oil and then solution of other vehicles.
(ii) One lot of the test substance should be used, if possible,
throughout the duration of the study, and the research sample should be
stored under conditions that maintain its purity and stability. Prior to
the initiation of the study, there should be a characterization of the
test substance, including the purity of the test compound and if
technically feasible, the name and
[[Page 356]]
quantities of unknown contaminants and impurities.
(iii) If the test substance is dissolved or suspended in a vehicle,
the period during which the test substance is stable in such a mixture
should be determined prior to the initiation of the study. Its
homogeneity and concentration should be determined prior to the
initiation of the study and periodically during the study. Statistically
randomized samples of the mixture should be analyzed to ensure that
proper mixing, formulation, and storage procedures are being followed,
and that the appropriate concentration of the test or control substance
is contained in the mixture.
(3) Control groups. A concurrent control group is required. This
group must be an untreated or sham-treated control group or, if a
vehicle is used in the application of the test substance, a vehicle
control group. If the toxic properties of the vehicle are not known or
not available, both untreated/sham-treated and vehicle control groups
are required.
(4) Satellite group. A satellite group of 20 animals (10 animals per
sex) may be treated with the high dose level for 90 days and observed
for reversibility, persistence, or delayed occurrence of toxic effects
for a post-treatment period of appropriate length, normally not less
than 28 days. In addition a control group of 20 animals (10 animals per
sex) should be added to the satellite study.
(5) Dose levels and dose selection. (i) In subchronic toxicity
tests, it is desirable to determine a dose-response relationship as well
as a NOEL. Therefore, at least three dose levels plus a control and,
where appropriate, a vehicle control (corresponding to the concentration
of vehicle at the highest dose level) group shall be used. Doses should
be spaced appropriately to produce test groups with a range of toxic
effects. The data should be sufficient to produce a dose-response curve.
(ii) The highest dose level should elicit signs of toxicity but not
produce severe skin irritation or an incidence of fatality which would
prevent a meaningful evaluation. If application of the test substance
produces severe skin irritation, the concentration may be reduced,
although this may result in a reduction in, or absence of, other toxic
effects at the high dose level. If the skin has been badly damaged early
in the study, it may be necessary to terminate the study and undertake a
new one at lower concentrations.
(iii) The intermediate dose levels should be spaced to produce a
gradation of toxic effects.
(iv) The lowest dose level should not produce any evidence of toxic
effects.
(6) Preparation of animal skin. Shortly before testing, fur must be
clipped from not less than 10% of the body surface area for application
of the test substance. In order to dose approximately 10% of the body
surface, the area starting at the scapulae (shoulders) to the wing of
the ileum (hipbone) and half way down the flank on each side of the
animal should be shaved. Shaving should be carried out approximately 24
hours before dosing. Repeated clipping or shaving is usually needed at
approximately weekly intervals. When clipping or shaving the fur, care
should be taken to avoid abrading the skin which could alter its
permeability.
(7) Preparation of test substance. (i) Liquid test substances are
generally used undiluted, except as indicated in paragraph (e)(5)(ii) of
this section.
(ii) Solids should be pulverized when possible. The substance should
be moistened sufficiently with water or, when necessary, a suitable
vehicle to ensure good contact with the skin. When a vehicle is used,
the influence of the vehicle on toxicity of, and penetration of the skin
by, the test substance should be taken into account.
(iii) The volume of application should be kept constant, e.g., less
than 300 [micro]L for the rat; different concentrations of test solution
shall be prepared for different dose levels.
(8) Administration of test substance. (i) The duration of exposure
should be at least for 90 days.
(ii) Ideally, the animals should be treated with test substance for
at least 6 hours per day on a 7-day per week basis. However, based on
practical considerations, application on a 5-day per week basis is
acceptable. Dosing should be conducted at approximately the same time
each day.
[[Page 357]]
(iii) The test substance must be applied uniformly over the
treatment site.
(iv) The surface area covered may be less for highly toxic
substances. As much of the area should be covered with as thin and
uniform a film as possible.
(v) During the exposure period, the test substance must be held in
contact with the skin with a porous gauze dressing (less than or equal
to 8 ply). The test site must be further covered with nonirritating tape
to retain the gauze dressing and the test substance and to ensure that
the animals cannot ingest the test substance. Restrainers may be used to
prevent the ingestion of the test substance, but complete immobilization
is not recommended. The test substance may be wiped from the skin after
the six-hour exposure period to prevent ingestion.
(9) Observation of animals. (i) Observations must be made at least
twice each day for morbidity and mortality. Appropriate actions should
be taken to minimize loss of animals to the study (e.g., necropsy or
refrigeration of those animals found dead and isolation or sacrifice of
weak or moribund animals). General clinical observations must be made at
least once a day, preferably at the same time each day, taking into
consideration the peak period of anticipated effects after dosing. The
clinical condition of the animal should be recorded.
(ii) A careful clinical examination must be made at least once
weekly. Observations should be detailed and carefully recorded,
preferably using explicity defined scales. Observations should include,
but not be limited to, evaluation of skin and fur, eyes and mucous
membranes, respiratory and circulatory effects, autonomic effects such
as salivation, central nervous system effects, including tremors and
convulsions, changes in the level of activity, gait and posture,
reactivity to handling or sensory stimuli, altered strength, and
stereotypes or bizarre behavior (e.g., self-mutilation, walking
backwards).
(iii) Signs of toxicity should be recorded as they are observed
including the time of onset, degree and duration.
(iv) Individual weights of animals must be determined shortly before
the test substance is administered, weekly thereafter, and at death.
(v) Food consumption must also be determined weekly if abnormal body
weight changes are observed.
(vi) Moribund animals should be removed and sacrificed when noticed
and the time of death should be recorded as precisely as possible.
(vii) At termination, all survivors in the control and treatment
groups must be sacrificed.
(10) Clinical pathology. Hematology and clinical chemistry
examinations must be made on all animals, including controls, of each
sex in each group. The hematology and clinical chemistry parameters
should be examined at terminal sacrifice at the end of the study.
Overnight fasting of the animals prior to blood sampling is recommended.
Overall, there is a need for a flexible approach in the measures
examined, depending on the observed or expected effects from a chemical,
and in the frequency of measures, depending on the duration of potential
chemical exposures.
(i) Hematology. The recommended parameters are red blood cell count,
hemoglobin concentration, hematocrit, mean corpuscular volume, mean
corpuscular hemoglobin, and mean corpuscular hemoglobin concentration,
white blood cell count, differential leukocyte count, platelet count,
and a measure of clotting potential, such as prothrombin time or
activated partial thromboplastin time.
(ii) Clinical chemistry. (A) Parameters which are considered
appropriate to all studies are electrolyte balance, carbohydrate
metabolism, and liver and kidney function. The selection of specific
tests will be influenced by observations on the mode of action of the
substance and signs of clinical toxicity.
(B) The recommended clinical chemistry determinations are potassium,
sodium, glucose, total cholesterol, urea nitrogen, creatinine, total
protein and albumin. More than 2 hepatic enzymes, (such as alanine
aminotransferase, aspartate aminotransferase, alkaline phosphatase,
sorbitol dehydrogenase, or gamma glutamyl transpeptidase)
[[Page 358]]
should also be measured. Measurements of additional enzymes (of hepatic
or other origin) and bile acids, may also be useful.
(C) If a test chemical has an effect on the hematopoietic system,
reticulocyte counts and bone marrow cytology may be indicated.
(D) Other determinations that should be carried out if the test
chemical is known or suspected of affecting related measures include
calcium, phosphorus, fasting triglycerides, hormones, methemoglobin, and
cholinesterases.
(iii) Optionally, the following urinalysis determinations could be
performed during the last week of the study using timed urine volume
collection: appearance, volume, osmolality or specific gravity, pH,
protein, glucose and blood/blood cells.
(11) Ophthalmological examination. Using an ophthalmoscope or an
equivalent device, ophthalmological examinations must be made on all
animals prior to the administration of the test substance and on all
high dose and control groups at termination. If changes in the eyes are
detected, all animals in the other dose groups must be examined.
(12) Gross necropsy. (i) All animals must be subjected to a full
gross necropsy which includes examination of the external surface of the
body, all orifices, and the cranial, thoracic and abdominal cavities and
their contents.
(ii) The liver, brain, kidneys, spleen, adrenals, testes,
epididymides, uterus, ovaries, thymus and heart must be trimmed and
weighed wet, as soon as possible after dissection.
(iii) The following organs and tissues, or representative samples
thereof, must be preserved in a suitable medium for possible future
histopathological examination:
(A) Digestive system--salivary glands, esophagus, stomach, duodenum,
jejunum, ileum, cecum, colon, rectum, liver, pancreas, gallbladder (when
present).
(B) Nervous system--brain (multiple sections, including cerebrum,
cerebellum and medulla/pons), pituitary, peripheral nerve (sciatic or
tibial, preferably in close proximity to the muscle), spinal cord (three
levels, cervical, mid-thoracic and lumbar), eyes (retina, optic nerve).
(C) Glandular system--adrenals, parathyroid, thyroid.
(D) Respiratory system--trachea, lungs, pharynx, larynx, nose.
(E) Cardiovascular/Hematopoietic system--aorta, heart, bone marrow
(and/or fresh aspirate), lymph nodes (preferably one lymph node covering
the route of administration and another one distant from the route of
administration to cover systemic effects), spleen, thymus.
(F) Urogenital system--kidneys, urinary bladder, prostate, testes,
epididymides, seminal vesicle(s), uterus, ovaries, female mammary gland.
(G) Other--all gross lesions and masses, skin (both treated and
adjacent untreated areas).
(13) Histopathology. (i) The following histopathology must be
performed:
(A) Full histopathology on the organs and tissues, listed in
paragraph (e)(12)(iii) of this section, of all animals in the control
and high dose groups and all animals that died or were sacrificed during
the study.
(B) All gross lesions in all animals.
(C) Target organs in all animals.
(D) When a satellite group is used, histopathology must be performed
on tissues and organs identified as showing toxic effects in the treated
groups.
(ii) If excessive early deaths or other problems occur in the high
dose group compromising the significance of the data, the next dose
level must be examined for complete histopathology.
(iii) An attempt should be made to correlate gross observations with
microscopic findings.
(iv) Tissues and organs designated for microscopic examination
should be fixed in 10% buffered formalin or a recognized suitable
fixative as soon as necropsy is performed and no less than 48 hours
prior to trimming.
(f) Data and reporting--(1) Treatment of results. (i) Data must be
summarized in tabular form, showing for each test group, number of
animals at the start of the test, the number of animals showing lesions,
the types of lesions and the percentage of animals displaying each type
of lesion.
(ii) When applicable, all observed results, qualitative and
quantitative,
[[Page 359]]
should be evaluated by an appropriate and generally acceptable
statistical method. Any generally accepted statistical method should be
used; the statistical methods including significance criteria should be
selected during the design of the study.
(2) Evaluation of study results. The findings of a subchronic dermal
toxicity study should be evaluated in conjunction with the findings of
preceding studies and considered in terms of toxic effects and the
necropsy and histopathological findings. The evaluation should include
the relationship between the dose of the test substance, the incidence
and severity of abnormalities including behavioral and clinical
abnormalities, gross lesions, identified target organs, body weight
changes, effect on mortality, and any other general or specific toxic
effects. A properly conducted 90-day subchronic dermal study should
provide information on the effects of repeated application of a
substance and a satisfactory estimation of a NOEL. It also can indicate
the need for an additional longer-term study and provide information on
the selection of dose levels.
(3) Test report. In addition to reporting requirements specified
under EPA Good Laboratory Practice Standards at 40 CFR part 792, subpart
J, the following specific information must be reported:
(i) Test substance characterization should include:
(A) Chemical identification.
(B) Lot or batch numbers.
(C) Physical properties.
(D) Purity/impurities.
(ii) Identification and composition of any vehicle if used.
(iii) Test system should contain data on:
(A) Species and strain of animals used and rationale for selection
if other than that recommended.
(B) Age including body weight data and sex.
(C) Test environment including cage conditions, ambient temperature,
humidity, and light/dark periods.
(D) Identification of animal diet.
(E) Acclimation period.
(iv) Test procedure should include the following data:
(A) Method of randomization used.
(B) Full description of experimental design and procedure.
(C) Dose regime including levels, method, and volume.
(v) Test results should include:
(A) Group animal data. Tabulation of toxic response data by species,
strain, sex and exposure level for:
(1) Number of animals exposed.
(2) Number of animals showing signs of toxicity.
(3) Number of animals dying.
(B) Individual animal data. Data should be presented as summary
(group mean) as well as for individual animals.
(1) Date of death during the study or whether animals survived to
termination.
(2) Date of observation of each abnormal sign and its subsequent
course.
(3) Body weight data.
(4) Feed consumption data, when collected.
(5) Results of ophthalmological examination.
(6) Results of hematological tests performed.
(7) Results of clinical chemistry tests performed.
(8) Results of urinalysis, when performed.
(9) Results of observations made.
(10) Necropsy findings, including absolute and relative (to body
weight) organ weight data.
(11) Detailed description of all histopathological findings.
(12) Statistical treatment of results, where appropriate.
(g) Quality control. A system must be developed and maintained to
assure and document adequate performance of laboratory equipment. The
study must be conducted in compliance with the Good Laboratory Practice
(GLP) regulations.
(h) References. For additional background information on this test
guideline, the following references should be consulted. These
references are available for inspection at the TSCA Nonconfidential
Information Center, Rm. NE-B607, Environmental Protection Agency, 401 M
St., NW., Washington, DC, 12 noon to 4 p.m., Monday through Friday,
except legal holidays.
(1) Organization for Economic Cooperation and Development.
Guidelines
[[Page 360]]
for Testing of Chemicals, Section 4-Health Effects, Part 411 Subchronic
Toxicity Studies, Paris, 1981.
(2) Weingand K, Brown G, Hall R et al. (1996). Harmonization of
Animal Clinical Pathology Testing in Toxicity and Safety Studies.
Fundam. & Appl. Toxicol. 29:198-201.
[65 FR 78786, Dec. 15, 2000]